APOA1: a Protein with Multiple Therapeutic Functions.

Publication Type:
Journal Article
Curr Atheroscler Rep, 2021, 23, (3), pp. 11
Issue Date:
Filename Description Size
Cochran2021_Article_APOA1AProteinWithMultipleThera.pdfPublished version524.88 kB
Adobe PDF
Full metadata record
PURPOSE OF THE REVIEW: Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states. RECENT FINDINGS: Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1. APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.
Please use this identifier to cite or link to this item: